Cardiff Oncology Inc (CRDF) Implied Volatility Current

Tracking CRDF implied volatility helps you identify when options premiums on Cardiff Oncology Inc are historically cheap or expensive, and where the best trades are hiding. Cardiff Oncology Inc implied volatility reflects the market's expectation of future price movement: when CRDF IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Cardiff Oncology Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CRDF, tracking metrics like CRDF IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CRDF signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers.

The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CRDF implied volatility sits today versus where it has been. Our scanner ranks Cardiff Oncology Inc implied volatility against its historical range, surfaces extremes in CRDF IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Cardiff Oncology Inc IV is rich or cheap — measure it, then act on it.